Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Rare Case of Amphiphysin-associated Stiff Person Syndrome in a Male Patient with Breast Cancer
Autoimmune Neurology
P9 - Poster Session 9 (12:00 PM-1:00 PM)
15-006

To describe a male patient with amphiphysin-associated Stiff-Person Syndrome(SPS) secondary to underlying breast cancer.

SPS is a rare neuroimmunological disorder that has varying clinical presentations and can be associated with different autoantibodies. Amphiphysin antibodies are most often associated with paraneoplastic-related SPS.

Case-report

A 53-year-old man developed progressive upper-torso and arm stiffness/rigidity and gait instability. Subsequently, he developed foot spasms along with anxiety/agoraphobia and was diagnosed with psychogenic dystonia. Despite cognitive-behavioral-therapy, he experienced more symptoms over the ensuing year(leg stiffness requiring a cane and arm spasms) and predictable triggers for his symptoms(stress, loud noises, cold, and open spaces).

Two-years after symptom onset, he was diagnosed with SPS based on a work-up that identified positive-serum (1:7680) and CSF (1:64) amphiphysin-antibodies. Initial malignancy work-up was unremarkable including mammogram and whole-body PET CT-scan. Over the following year, he was treated with a variety of immune-therapies including IVIG, PLEX, and cyclophosphamide. His gait improved but stiffness and spasms worsened. Repeat malignancy work-up (approximately three-years out from initial symptom-onset) identified left-sided gynecomastia secondary to a retro-areolar nodule.  Core-diagnostic biopsy revealed grade-2 invasive ductal carcinoma. These results prompted a left-sided modified radical-mastectomy followed by adjuvant chemotherapy and radiation-therapy. Three-months after completing his cancer treatment, repeat amphiphysin-antibody testing was negative, although, neurophysiological-studies still demonstrated signs of SPS. Three-months out from his cancer treatment, he has experienced significant improvement in most of his symptoms and is able to walk unsupported; modified-Rankin Scale improved from grade-4 to grade-2 and his 25-foot timed walk went from 8.6 to 4.9 seconds without-assistance.

We present a rare case of paraneoplastic-related SPS in a man with breast cancer. Upper greater than lower torso/body presentations can occur in SPS particularly with amphiphysin-related-SPS. This case also highlights the importance of vigilant cancer-screening even if initial investigations are negative, especially in the setting of positive-amphiphysin antibody.

Authors/Disclosures
Loulwah Mukharesh, MD (.)
PRESENTER
Dr. Mukharesh has nothing to disclose.
Scott D. Newsome, DO, FÂé¶¹´«Ã½Ó³»­ (Johns Hopkins Hospital) Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. The institution of Dr. Newsome has received research support from Kyverna Therapeutics. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.